(Yicai Global) Nov. 21 -- Novartis AG [NYSE: NVS], the world's leading pharmaceutical company, has started mass production of its heart failure drug Entresto at its Changping plant in Beijing, 21st Century Business Herald reported.
The form will sell the product in the key first-tier markets of Beijing, Shanghai, Guangzhou, as well as in other provinces and cities across the country.
"China is one of Novartis' most important markets globally. With the support of favorable policy environment and economic development, Novartis has established world-class pharmaceutical R&D centers and manufacturing bases in China. We will continue to focus on innovative R&D and manufacturing", said Yin Xudong, head of Novartis Pharmaceuticals (Asia Pacific, Middle East and Africa) and president of Novartis (China).
Novartis has set up a biomedical research center in China more than 10 years ago. Novartis Shanghai R&D Center was established in 2016 with an additional USD1 billion investment, becoming the third largest R&D center in the world after Switzerland and the United States, the report said.
Novartis' Shanghai R&D center is capable of creating new drugs, and focuses on the research related to high-risk cancers in China and Asia, such as lung cancer, liver cancer, stomach cancer and other diseases.